Lonvoguran ziclumeran (NTLA-2002)
Lonvoguran ziclumeran (NTLA-2002) is a CRISPR-based gene-editing therapy targeting the plasma kallikrein gene, developed by Intellia Therapeutics for hereditary angioedema. The next event is the FDA decision on NTLA-2002, on Mar 10, 2027 (source).
- Company
- Intellia Therapeutics (NTLA) · Developer
- How it works
- CRISPR-based gene editing targeting plasma kallikrein
- Approved
- Not approved in any market we track
Development by disease
| Hereditary angioedema | Filed |
Upcoming events
Firm dates · a specific day set by the company or regulator
Later
- Mar 10in 148 daysNTLA-2002 · FDA decision · Hereditary angioedema
Past results and milestones
- Aug 6, 2026reportedHAELO Phase 3 trial met primary endpoint with 87% reduction in mean monthly attacks (p<0.0001) and all key secondary endpoints. Data presented at EAACI and published in New England Journal of Medicine in June 2026. Source
- Apr 1, 2026Intellia initiated a rolling BLA submission for lonvo-z (NTLA-2002) for hereditary angioedema in April 2026 under RMAT designation, allowing submission of portions on an ongoing basis with FDA review acceleration opportunity. Source
- Aug 7, 2025HAELO recruitment ended ahead of schedule during Q2 2025; Phase 3 HAELO randomization expected to complete in Q3 2025. Source